This review summarizes current knowledge on post-acute sequelae of COVID-19 (PASC) and post-COVID-19 condition (PCC) in children and adolescents. PASC, also known as Long COVID, refers to a wide range of unspecific symptoms occurring more than 4 weeks after a confirmed or probable SARS-CoV-2 infection, without another medical explanation. PCC is defined by the WHO as symptoms occurring within 3 months of acute COVID-19, lasting at least 2 months, and limiting daily activities. PASC in children often follows mild infections and may persist for more than a year, leading to significant disability. Common symptoms include fatigue, exertion intolerance, and anxiety. Some patients may have postural tachycardia syndrome (PoTS) or meet the criteria for myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). No diagnostic marker has been established, and differential diagnosis remains challenging. Treatment includes self-management and strategies to alleviate symptoms. PASC in pediatrics presents with varied severity and duration, requiring a stepped, interdisciplinary, and individualized approach. Current healthcare structures need adaptation to meet the medical and psychosocial needs of children with PASC or similar conditions. The review highlights the importance of early identification, appropriate diagnostics, and management strategies, including non-pharmaceutical and pharmaceutical approaches. It also discusses the challenges of post-exertional malaise (PEM) and the need for research to improve understanding and treatment of PASC in children. The review emphasizes the importance of holistic care, including psychological and social support, and the need for further research to address the gaps in knowledge and improve patient outcomes.This review summarizes current knowledge on post-acute sequelae of COVID-19 (PASC) and post-COVID-19 condition (PCC) in children and adolescents. PASC, also known as Long COVID, refers to a wide range of unspecific symptoms occurring more than 4 weeks after a confirmed or probable SARS-CoV-2 infection, without another medical explanation. PCC is defined by the WHO as symptoms occurring within 3 months of acute COVID-19, lasting at least 2 months, and limiting daily activities. PASC in children often follows mild infections and may persist for more than a year, leading to significant disability. Common symptoms include fatigue, exertion intolerance, and anxiety. Some patients may have postural tachycardia syndrome (PoTS) or meet the criteria for myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). No diagnostic marker has been established, and differential diagnosis remains challenging. Treatment includes self-management and strategies to alleviate symptoms. PASC in pediatrics presents with varied severity and duration, requiring a stepped, interdisciplinary, and individualized approach. Current healthcare structures need adaptation to meet the medical and psychosocial needs of children with PASC or similar conditions. The review highlights the importance of early identification, appropriate diagnostics, and management strategies, including non-pharmaceutical and pharmaceutical approaches. It also discusses the challenges of post-exertional malaise (PEM) and the need for research to improve understanding and treatment of PASC in children. The review emphasizes the importance of holistic care, including psychological and social support, and the need for further research to address the gaps in knowledge and improve patient outcomes.